New South Wales Health warned on 19 October about unapproved peptide products promoted online for anti-ageing, weight loss and injury repair. The authority raises concerns about uncertain contents, strength and contamination. Professional-looking packaging is not evidence that a product has been assessed for safety or that its marketing claims are established. [1]
What the hospital figures show
The 17 October report counts 1,180 emergency visits from July 2025 through September 2026, with monthly numbers rising from five to 217. These are visits, not unique people. Triage mentions identify use; they do not prove it caused the visit or admission. [2]
Why the distinction matters
Incomplete recording and misclassification limit the findings. The report is a surveillance signal, not a population-wide estimate of use. It cannot establish how many people were poisoned by a particular product. [2]
Regulators’ concern is product quality
Australia’s TGA has separately warned that unapproved products have not been assessed for quality, safety and effectiveness. Concerns include manufacturing, sterility and uncertain contents; reported adverse events include liver damage and allergic reactions. Those warnings do not identify the contents of every vial sold online, nor prove that every reported event has the same cause. [3]
Not all peptides are the same
TGA guidance distinguishes unapproved products from approved peptide medicines, including insulin. A chemical category is not a quality certificate, but neither is it evidence that every medicine in that category is unsafe. The regulatory statements concern Australia; they should not be recast as a universal legal ban applying identically in every country. [4]
For readers — Nove.news context
An online testimonial and an attractive label cannot replace an assessment of a specific product. Anyone concerned about a product they have used should seek a qualified clinician’s advice. Severe or rapidly worsening symptoms require urgent local medical care; this report does not provide instructions for selecting, dosing or injecting unapproved substances.
What comes next
Watch for updated surveillance and regulatory notices. The photograph shows generic laboratory vials; their contents are not identified as peptides, medicines or products involved in the report.
